Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Launch of Onglyza is expected to begin in the fourth quarter of 2009
Subscribe to our email newsletter
AstraZeneca and Bristol-Myers Squibb have reported that the European Commission has granted marketing authorisation for Onglyza (saxagliptin) across 27 countries of the EU.
Onglyza is indicated as a once-daily 5mg oral tablet dose in adult patients with type 2 diabetes mellitus to improve glycaemic control.
Reportedly, the marketing authorisation is based on data submitted from a comprehensive clinical development programme, that included six core phase III registrational trials and a phase IIIB study comparing saxagliptin plus metformin with sitagliptin plus metformin.
The registrational trials assessed the safety and efficacy of Onglyza and involved 4,148 patients with type 2 diabetes, including 3,021 patients treated with Onglyza.
Onglyza is to be launched in Europe through the worldwide collaboration of Bristol-Myers Squibb and AstraZeneca to enable the companies to research, develop and commercialise select investigational medicines for the treatment of type 2 diabetes. The launch of ONGLYZA is expected to begin in the fourth quarter of 2009.
Beatrice Cazala, president, Bristol-Myers Squibb, Europe, and president, Global Commercialisation, said: “The European Commission decision marks an important milestone in the alliance between Bristol-Myers Squibb and AstraZeneca.”